Malignant gliomas: strategies to increase the effectiveness of targeted molecular treatment (Q36499234)

14 August 2017

1 reference

title

Malignant gliomas: strategies to increase the effectiveness of targeted molecular treatment (English)

1 reference

14 August 2017

1

Patrick Y Wen

1 reference

14 August 2017

Santosh Kesari

2

1 reference

14 August 2017

Jan Drappatz

series ordinal

3

1 reference

14 August 2017

publication date

1 May 2006

1 reference

Expert Review of Anticancer Therapy

14 August 2017

published in

1 reference

14 August 2017

volume

6

1 reference

14 August 2017

issue

5

1 reference

14 August 2017

page(s)

733-754

1 reference

Primary brain tumours in adults.

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Intracellular signal transduction pathway proteins as targets for cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Therapy for recurrent malignant glioma in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Recent advances in the treatment of malignant astrocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Emerging molecular therapies for brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Role of tyrosine kinase inhibitors in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 1: growth factor and Ras signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 2: PI3K/Akt/PTEN, mTOR, SHH/PTCH and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Development of novel targeted therapies in the treatment of malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Malignant glioma: genetics and biology of a grave matter.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Recent advances in the molecular genetics of primary gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Altered molecular pathways in gliomas: an overview of clinically relevant issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Molecular changes in gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Molecular pathogenesis of astrocytic tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Distinct transcription profiles of primary and secondary glioblastoma subgroups.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Characterization of gene expression profiles associated with glioma progression using oligonucleotide-based microarray analysis and real-time reverse transcription-polymerase chain reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Molecular analysis of glioblastoma: pathway profiling and its implications for patient therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Genetic and signaling pathway alterations in glioblastoma relevance to novel targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Gene expression profiling identifies molecular subtypes of gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Perspectives on the development of a molecularly targeted agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Phase II trial of gefitinib in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Biomarkers to predict response to epidermal growth factor receptor inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Somatic mutations of EGFR in colorectal cancers and glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Expression of PDGF and PDGF receptors in human astrocytoma operation specimens supports the existence of an autocrine loop.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Phase I trial of tipifarnib in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

VEGF-Trap: a VEGF blocker with potent antitumor effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Histone deacetylases and cancer: causes and therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

The proteasome: a suitable antineoplastic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

DNA-microarray analysis of brain cancer: molecular classification for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Towards a proteome-scale map of the human protein–protein interaction network

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Network biology: understanding the cell's functional organization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Tumor necrosis factor-alpha-induced protein 3 as a putative regulator of nuclear factor-kappaB-mediated resistance to O6-alkylating agents in human glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Functional network analysis reveals extended gliomagenesis pathway maps and three novel MYC-interacting genes in human gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

In vitro and in vivo activity of the nuclear factor-kappaB inhibitor sulfasalazine in human glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Co-inhibition of epidermal growth factor receptor and type 1 insulin-like growth factor receptor synergistically sensitizes human malignant glioma cells to CD95L-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Simultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Targeting the mitogen-activated protein kinase cascade to treat cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Synergistic interaction between 17-AAG and phosphatidylinositol 3-kinase inhibition in human malignant glioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

The phosphorylation of EphB2 receptor regulates migration and invasion of human glioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Inhibition of ILK in PTEN-mutant human glioblastomas inhibits PKB/Akt activation, induces apoptosis, and delays tumor growth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Targeting integrin-linked kinase inhibits Akt signaling pathways and decreases tumor progression of human glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Lyn kinase activity is the predominant cellular SRC kinase activity in glioblastoma tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

HEF1 is a necessary and specific downstream effector of FAK that promotes the migration of glioblastoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

The emerging normal and disease-related roles of anaplastic lymphoma kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Cell-cycle targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

New opportunities in chemosensitization and radiosensitization: modulating the DNA-damage response

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

An inhibitor of Bcl-2 family proteins induces regression of solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

The inhibitors of apoptosis: there is more to life than Bcl2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Targeting the IAP family of caspase inhibitors as an emerging therapeutic strategy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Targeting XIAP for the treatment of malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Cannabinoids: potential anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Targeting cell cycle and apoptosis for the treatment of human malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Targeting the cell cycle: a new approach to cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Molecular neuro-oncology and the development of targeted therapeutic strategies for brain tumors. Part 5: apoptosis and cell cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Apoptosis-targeted therapies for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Targeted induction of apoptosis in cancer management: the emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Activation of chemokine receptor CXCR4 in malignant glioma cells promotes the production of vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Cannabinoids selectively inhibit proliferation and induce death of cultured human glioblastoma multiforme cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Applications of mouse glioma models in preclinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Drug discovery: playing dirty

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

HSP90 and the chaperoning of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Combining radiation and molecular targeting in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Agents with selective estrogen receptor (ER) modulator activity induce apoptosis in vitro and in vivo in ER-negative glioma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Novel radiation-enhancing agents in malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Radiation and new molecular agents, part II: targeting HDAC, HSP90, IGF-1R, PI3K, and Ras.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

The contribution of epidermal growth factor receptor (EGFR) signaling pathway to radioresistance in human gliomas: a review of preclinical and correlative clinical data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Molecular strategies targeting the host component of cancer to enhance tumor response to radiation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Tumor radiosensitizers--current status of development of various approaches: report of an International Atomic Energy Agency meeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Mechanisms of disease: Radiosensitization by epidermal growth factor receptor inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Imatinib mesylate radiosensitizes human glioblastoma cells through inhibition of platelet-derived growth factor receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

STI571 (Gleevec) improves tumor growth delay and survival in irradiated mouse models of glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Farnesyltransferase inhibitor, R115777, reverses the resistance of human glioma cell lines to ionizing radiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Enhanced radiation damage of tumor vasculature by mTOR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Combining radiotherapy and angiogenesis inhibitors: clinical trial design

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Cooperative antitumor effect of multitargeted kinase inhibitor ZD6474 and ionizing radiation in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinase activity in combination with radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

The P140K mutant of human O(6)-methylguanine-DNA-methyltransferase (MGMT) confers resistance in vitro and in vivo to temozolomide in combination with the novel MGMT inactivator O(6)-(4-bromothenyl)guanine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Chemopotentiation by PARP inhibitors in cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Potentiation of chemotherapeutic agents following antagonism of nuclear factor kappa B in human gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Molecular mechanisms of brain tumor edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Clinical pharmacokinetics of imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Modulation of the blood-brain barrier in oncology: therapeutic opportunities for the treatment of brain tumours?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Modulation of drug transporters at the blood-brain barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Interleukin-13 receptor-directed cytotoxin for malignant glioma therapy: from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Interleukin-4-Pseudomonas exotoxin chimeric fusion protein for malignant glioma therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malig

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

The progress and promise of molecular imaging probes in oncologic drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Molecular optical imaging: applications leading to the development of present day therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

21 January 2018

Imaging in neurooncology

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Medical management of patients with brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Dynamic magnetic resonance perfusion imaging of brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Molecular imaging of antiangiogenic agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Quantification of blood flow in brain tumors: comparison of arterial spin labeling and dynamic susceptibility-weighted contrast-enhanced MR imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

YKL-40 expression is associated with poorer response to radiation and shorter overall survival in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737140.6.5.733

21 January 2018

Identifiers

DOI

10.1586/14737140.6.5.733

1 reference

14 August 2017

1 reference